Delayed short-term tamoxifen treatment does not promote remyelination or neuron sparing after spinal cord injury
Open accessAbstract
The tamoxifen-dependent Cre/lox system in transgenic mice has become an important research tool across all scientific disciplines for manipulating gene expression in specific cell types. In these mouse models, Cre-recombination is not induced until tamoxifen is administered, which allows researchers to have temporal control of genetic modifications. Interestingly, tamoxifen has been identified as a potential therapy for spinal cord injury (SCI) and traumatic brain injury patients due to its neuroprotective properties. It is also reparative in that it stimulates oligodendrocyte differentiation and remyelination after toxin-induced demyelination. However, it is unknown whether tamoxifen is neuroprotective and neuroreparative when administration is delayed after SCI. To properly interpret data from transgenic mice in which tamoxifen treatment is delayed after SCI, it is necessary to identify the effects of tamoxifen alone on anatomical and functional recovery. In this study, female and male mice received a moderate mid-thoracic spinal cord contusion. Mice were then gavaged with corn oil or a high dose of tamoxifen from 19-22 days post-injury, and sacrificed 42 days post-injury. All mice underwent behavioral testing for the duration of the study, which revealed that tamoxifen treatment did not impact hindlimb motor recovery. Similarly, histological analyses revealed that tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination, but tamoxifen did decrease the number of neurons in the dorsal and ventral horn. Semi-thin sections confirmed that axon demyelination and remyelination were unaffected by tamoxifen. Sex-specific responses to tamoxifen were also assessed, and there were no significant differences between female and male mice. These data suggest that delayed tamoxifen administration after SCI does not change functional recovery or improve tissue sparing in female or male mice.
AI snapshot
Written from the paper’s full text.
TL;DR
Delayed short-term tamoxifen treatment (300 mg/kg oral gavage, 19–22 days post-injury) after moderate mouse spinal cord contusion did not improve hindlimb motor recovery or most histological repair measures. Tamoxifen-treated mice did have significantly fewer dorsal and ventral horn neurons overall, though no sex-specific effects were detected.
Key findings
- Tamoxifen gavage from 19–22 dpi did not alter BMS scores, post-gavage BMS subscores, missed steps on the automated horizontal ladder (all groups averaged 21–23 missed steps), or activity-box measures; it transiently increased lethargy during gavage (1.5-fold decrease in time spent moving, not significant).
- No significant tamoxifen effects were found for white matter sparing, total axon area (NF-H), axon sprouting (GAP-43), lesion size, GFAP astrocyte reactivity, EdU+ cell proliferation, NG2+ or CD68+ proliferating cells, oligodendrocyte number, intact nodes of Ranvier, or semi-thin-section demyelination/remyelination measures.
- Tamoxifen-treated mice had significantly fewer neurons overall in the dorsal horn (p = 0.0438) and ventral horn (p = 0.0431) compared with controls, but post hoc comparisons at specific distances rostral or caudal to the epicenter were not significant.
- Sex had no significant effect on histology or post-treatment behavior; male mice had higher BMS subscores at 14 dpi, before tamoxifen administration.
Methods
- Twelve-week-old female and male C57BL/6J mice received a moderate mid-thoracic contusion at T9 (75 kDyne target; mean force 77.15 kDyne, mean displacement 600.30 μm). At 19 dpi, mice were randomized to tamoxifen (300 mg/kg oral gavage, 19–22 dpi; n = 9 male, 10 female) or corn oil (n = 8 male, 9 female), with sacrifice at 42 dpi.
- Behavioral testing included Basso Mouse Scale, automated horizontal ladder, and activity box. Histological analyses included eriochrome cyanine white matter sparing, NeuN neuron counts, NF-H/GAP-43 axon and sprouting measures, GFAP, EdU proliferation, NG2/CD68, GSTπ oligodendrocytes, Kv1.2/Caspr nodes of Ranvier, and toluidine blue semi-thin sections.
- Data were analyzed blinded using two-way repeated measures ANOVA or mixed-effects models with Šídák post hoc tests, with significance at p < 0.05.
Limitations
- The paper states that the high tamoxifen dose (300 mg/kg, compared with 1 mg/kg in prior studies) may have been toxic and possibly induced neuronal cell death, though neuron density at specific distances from the epicenter was not changed. It also states that delayed dosing after spontaneous motor recovery and glial scar formation may explain the lack of effect.
- Evident from the text: the semi-thin Epon/toluidine blue remyelination analysis used very small groups (corn oil female n = 1–3; tamoxifen female n = 1–3; corn oil male n = 3; tamoxifen male n = 3), limiting power for that outcome.
- Evident from the text: the study tests one injury model, one delayed 4-day gavage regimen, and one high dose, so dose-response and other timing regimens are not addressed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
64 of 109 cited sources checked · 24 supported · 3 flagged · accuracy not yet measured
- Premisecitation
After SCI, remyelination does not begin until 2-3 weeks post-injury.
“After SCI, remyelination does not begin until 2–3 weeks post-injury, therefore delayed tamoxifen treatment is required when using Cre mice to manipulate gene expression during this time frame [44].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [44] ZC Hesp, 2015, Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats, J Neurosci source
The Discussion states that progenitors can remyelinate axons and that studies have shown this response occurs during the first two weeks after SCI. That contradicts the claim that remyelination does not begin until 2–3 weeks post-injury. The source’s page number is not available in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
- Premisecitation
Tamoxifen given via oral gavage for 4 consecutive days is sufficient to induce Cre recombination in transgenic mice.
“Tamoxifen was given via oral gavage for 4 consecutive days; this dosing regimen is sufficient to induce Cre recombination in transgenic mice [44]”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [44] ZC Hesp, 2015, Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats, J Neurosci source
The sections on generating PDGFRα-CreER:mT/mG and PDGFRα-ROSA mice report that four consecutive days of oral tamoxifen induced recombination in those transgenic lines. The copy does not specify oral gavage, so it does not establish that particular administration method. (LLM, conf=0.84)
Experimental — accuracy not yet measured
- Premisecitation
Tamoxifen has shown neuroprotective effects in models of stroke, dementia, multiple sclerosis, Parkinson's disease, traumatic brain injury, and spinal cord injury.
“tamoxifen crosses the blood-brain barrier [32] and has shown neuroprotective effects in models of stroke [33], dementia [34], multiple sclerosis [35], Parkinson’s disease [36], traumatic brain injury [37], and SCI [38].”
Quote in the paperSubstantial claim2 of 3 sources checked- cites [33] HK Kimelberg, 2000, Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion, Neuroreport source
- cites [34] LM Sun, 2016, Long-term use of tamoxifen reduces the risk of dementia: A nationwide population-based cohort study, QJM source
The Results report a lower dementia risk among breast cancer patients who used tamoxifen for at least five years. That supports the dementia-related part of the citation, but this was an observational study of patients, not a dementia model demonstrating a neuroprotective effect. The other conditions in the sentence have separate citations and are not attributed to this paper. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [35] GA Gonzalez, 2016, Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system, Sci Rep source
The Results section reports that tamoxifen accelerated remyelination in rats with experimentally induced CNS lesions, a finding relevant to multiple sclerosis. But the study used an ethidium-bromide demyelination model, not a model of multiple sclerosis itself, and measured myelin repair rather than a direct neuroprotective effect. Citation [35] is attached only to the multiple-sclerosis part of the citing sentence; the other conditions are outside this verdict. (LLM, conf=0.86)
Experimental — accuracy not yet measured
- Premisecitation
Healthy, myelinated axons contain organized clusters of proteins within and surrounding the node of Ranvier, including Caspr in the paranode and Kv1.2 in the juxtaparanode.
“Healthy, myelinated axons contain organized clusters of proteins within and surrounding the node of Ranvier, which includes contactin associated protein (Caspr) in the paranode and the potassium voltage-gated ion channel, Kv1.2, in the juxtaparanode [60–62].”
Quote in the paperSubstantial claim2 of 3 sources checked- cites [60] S Einheber, 1997, The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination, J Cell Biol source
- cites [61] S Karimi-Abdolrezaee, 2004, Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma, Eur J Neurosci source
- cites [62] MN Rasband, 2016, The Nodes of Ranvier: Molecular Assembly and Maintenance, Cold Spring Harb Perspect BiolMar source
- Interpretationown data
These results contradict other CNS trauma studies that show tamoxifen improves anatomical and motor recovery in female and male SCI rodents.
“These results contradict other CNS trauma studies that show tamoxifen improves anatomical and motor recovery in female and male SCI rodents [39–41, 55], but this is likely attributed to differences in the timing of dosing.”
Quote in the paperSubstantial claim3 of 4 sources checked- cites [39] B de la Torre Valdovinos, 2016, Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats, J Vet Med source
The Introduction and Discussion report beneficial effects of tamoxifen in rats after spinal cord injury, and the Conclusions describe earlier positive neuroprotective effects in rodents. But this paper’s own anatomical and gait-recovery findings are from cats; our copy does not establish those combined outcomes in both female and male SCI rodents. No page numbers were provided for these passages. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [40] L Mosquera, 2014, Tamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: Their antioxidant effect and role of estrogen receptor alpha, Brain Res source
- cites [41] DS Tian, 2009, Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats, J Neurochem source
- cites [55] JM Colón, 2016, Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats, J Neurotrauma source
- Premisecitation
After SCI, NG2 cell proliferation increases 50-fold as NG2 cells proliferate to replace NG2 cells and OLs lost from injury.
“Less than 1% of glial cells divide in the uninjured rodent spinal cord [75]; however, after SCI, NG2 cell proliferation increases 50-fold as NG2 cells proliferate to replace NG2 cells and OLs lost from injury [44, 47].”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [44] ZC Hesp, 2015, Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats, J Neurosci source
The Introduction says SCI induces robust NG2-cell proliferation and that dividing NG2 cells give rise to new oligodendrocytes. The section ‘OL progenitors proliferate for at least 4 weeks after SCI in rats’ also reports new NG2 cells, but it does not substantiate a 50-fold increase: its stated figure is 3- to 9-fold above controls as late as 10 weeks after injury. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [47] R Tripathi, 2007, Prominent oligodendrocyte genesis along the border of spinal contusion lesions, Glia source
- Premisecitation
This significant increase in macrophage/microglia and NG2 cell proliferation is maintained for months post-injury.
“This significant increase in macrophage/microglia and NG2 cell proliferation is maintained for months post-injury [2, 44]; therefore, it is not surprising that our data reveal ~25% of the NG2+ cells and CD68+ cells are EdU+ at 42pi.”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites [2] JC Fleming, 2006, The cellular inflammatory response in human spinal cords after injury, Brain source
The quantitative analysis and time-course section reports significantly greater CD68-immunoreactive microglia/macrophage area weeks to months after spinal cord injury. That measures cell presence and staining, not sustained proliferation; the passages do not address NG2-cell proliferation (searched: NG2, proliferation, and cell-division markers). (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [44] ZC Hesp, 2015, Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats, J Neurosci source
The section 'OL progenitors proliferate for at least 4 weeks after SCI in rats' reports significantly increased NG2-cell proliferation at 1–4 weeks and levels 3–9 times above controls as late as 10 weeks, though it does not state that the later increase was statistically significant. The paper does not establish that macrophage/microglia proliferation remains increased for months; its cell-counting methods explicitly excluded macrophages from NG2-cell counts. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measured
- Findingown data
There was no change in the overall area of large caliber axons.
“There was also no change the overall area of large caliber axons.”
- Also stated in: § Abstract · plain
“tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
BMS subscores were unaffected by tamoxifen administration at any time post-injury.
“Overall, BMS subscores were significantly increased in male mice 14dpi, but unaffected by tamoxifen administration at any time post-injury (Fig 2C).”
Quote in the paperSubstantial claim - Findingown data
EdU+ cells were highest close to the lesion for all groups.
“EdU+ cells were highest close to the lesion for all groups (Fig 7A and 7B).”
Quote in the paperNot a substantial claim - Findingown data
The percent of remyelinated, demyelinated, and spared myelinated axons was not different between groups near or distal to the lesion epicenter.
“The percent of remyelinated, demyelinated, and spared myelinated axons was not different between groups near or distal to the lesion epicenter (Fig 9F).”
Quote in the paperSubstantial claim - Findingown data
Ambulation of tamoxifen mice recovered by 29 dpi.
“Ambulation of tamoxifen mice recovered by 29dpi.”
Quote in the paperNot a substantial claim - Findingown data
The number of missed steps on the automated horizontal ladder was not statistically significant between groups.
“The number of missed steps on the automated horizontal ladder was not statistically significant between groups.”
Quote in the paperSubstantial claim - Findingown data
Tamoxifen had no effect on myelination.
“tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination”
Quote in the paperSubstantial claim - Findingown data
All mice experienced similar levels of hindlimb function and tissue repair, regardless of sex or treatment group.
“Our data revealed that all mice experienced similar levels of hindlimb function and tissue repair, regardless of sex or treatment group.”
Quote in the paperSubstantial claim - Findingown data
Semi-thin sections confirmed that axon demyelination and remyelination were unaffected by tamoxifen.
“Semi-thin sections confirmed that axon demyelination and remyelination were unaffected by tamoxifen.”
Quote in the paperSubstantial claim - Findingown data
There were no significant differences between groups in NF-H+ area at any distance from the lesion epicenter.
“Overall, there were no significant differences between groups at any distance.”
Quote in the paperSubstantial claim - Findingown data
Following moderate spinal cord contusion, spontaneous hindlimb motor recovery occurred in all our injury groups until plateauing at 14pi.
“Following moderate spinal cord contusion, spontaneous hindlimb motor recovery occurred in all our injury groups until plateauing at 14pi.”
Quote in the paperSubstantial claim - Findingown data
Tamoxifen gavage reduced the number of ambulatory activities at 22 dpi in female and male mice.
“Tamoxifen gavage reduced the number of ambulatory activities at 22dpi in female and male mice.”
Quote in the paperNot a substantial claim - Findingown data
Post hoc analysis did not show significant differences in the number of NeuN+ cells rostral or caudal to the lesion epicenter within specific subregions.
“However, post hoc analysis did not show significant differences in the number of NeuN+ cells rostral or caudal to the lesion epicenter within specific subregions (Fig 4A–4D).”
Quote in the paperSubstantial claim - Findingown data
Tamoxifen had no effect on oligodendrocyte number.
“tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination”
Quote in the paperSubstantial claim - Findingown data
No significant differences were detected between control and tamoxifen groups in the number of EdU+ cells.
“No significant differences were detected between control and tamoxifen groups.”
- Also stated in: § Abstract · plain
“tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
In all groups, the number of proliferating cells gradually decreased as the distance from the epicenter increased.
“In all groups, the number of proliferating cells gradually decreased as the distance from the epicenter increased (Fig 7A and 7B).”
Quote in the paperNot a substantial claim - Findingown data
Tamoxifen-treated mice had significantly fewer neurons in the ventral horn compared to control mice (p = 0.0431).
“Tamoxifen-treated mice had significantly fewer neurons in the dorsal horn (two-way repeated measures ANOVA; p = 0.0438) and ventral horn (p = 0.0431) compared to control mice (Fig 4A–4D).”
- Also stated in: § Abstract · plain
“but tamoxifen did decrease the number of neurons in the dorsal and ventral horn.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
During corn oil or tamoxifen gavage, sex no longer significantly impacted motor recovery.
“However, during corn oil or tamoxifen gavage, sex no longer significantly impacted motor recovery.”
Quote in the paperNot a substantial claim - Findingown data
There were no significant differences between female and male mice in sex-specific responses to tamoxifen.
“Sex-specific responses to tamoxifen were also assessed, and there were no significant differences between female and male mice.”
Quote in the paperNot a substantial claim - Findingown data
At 14 dpi, male mice scored significantly higher on the BMS subscore scale, averaging ~3.5 compared to an average of 0 for female mice.
“At 14dpi, male mice scored significantly higher on the BMS subscore scale, averaging a score of ~3.5 compared to an average of 0 for female mice.”
Quote in the paperNot a substantial claim - Findingown data
Tamoxifen-treated mice had significantly fewer neurons in the dorsal horn compared to control mice (p = 0.0438).
“Tamoxifen-treated mice had significantly fewer neurons in the dorsal horn (two-way repeated measures ANOVA; p = 0.0438) and ventral horn (p = 0.0431) compared to control mice (Fig 4A–4D).”
- Also stated in: § Abstract · plain
“but tamoxifen did decrease the number of neurons in the dorsal and ventral horn.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
No significant differences associated with sex or drug administration were detected for total cell number or cell proliferation of NG2+ cells or CD68+ macrophages/microglia.
“No significant differences associated with sex or drug administration were detected for total cell number or cell proliferation of NG2+ cells or CD68+ macrophages/microglia (Fig 7).”
- Also stated in: § Phagocytic monocyte and NG2 cell proliferation are not affected by delayed short-term tamoxifen gavage after SCI · plain
“The data are not significantly different between control and tamoxifen mice or female and male mice at any distance from the lesion epicenter.”
- Also stated in: § Discussion · plain
“However, total and proliferating NG2 cells and phagocytic macrophages/microglia numbers were not different between groups.”
Quote in the paperSubstantial claim - Also stated in: § Phagocytic monocyte and NG2 cell proliferation are not affected by delayed short-term tamoxifen gavage after SCI · plain
- Findingown data
GAP-43+ immunolabeling was highest closest to the lesion epicenter in both tamoxifen and control mice, and then gradually decreased with increasing distance from the lesion.
“Growth associated protein-43 (GAP-43)+ immunolabeling was highest closest to the lesion epicenter in both tamoxifen and control mice, and then gradually decreased with increasing distance from the lesion (Fig 5A and 5C).”
Quote in the paperNot a substantial claim - Findingown data
When examining neurons at specific distances rostral and caudal to the lesion epicenter, tamoxifen did not change neuron density.
“However, when examining neurons at specific differences rostral and caudal to the lesion epicenter, tamoxifen did not change neuron density.”
Quote in the paperSubstantial claim - Findingown data
Axon sprouting and total axon density near the lesion border and in the lateral white matter rostral and caudal to the lesion cavity was similar between groups.
“In addition, axon sprouting and total axon density near the lesion border and in the lateral white matter rostral and caudal to the lesion cavity was similar between groups.”
Quote in the paperSubstantial claim - Findingown data
There were no significant differences in histology between female and male mice.
“Data analyses revealed no significant differences in histology between female and male mice.”
Quote in the paperSubstantial claim - Findingown data
BMS subscores were significantly higher for males at 14dpi.
“However, BMS subscores were significantly higher for males at 14dpi.”
Quote in the paperNot a substantial claim - Premisecitation
If tamoxifen treatment was delayed until 42 days after SCI, hindlimb motor recovery was not changed.
“if tamoxifen treatment was delayed until 42 days after SCI, then hindlimb motor recovery was not changed; the impact of delayed tamoxifen treatment on tissue repair was not assessed [43].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [43] J Guptarak, 2014, The cancer drug tamoxifen: A potential therapeutic treatment for spinal cord injury, J Neurotrauma source
- Interpretationown data
Tamoxifen gavage 19-22 dpi does not alter locomotor recovery.
“Collectively, these data show that tamoxifen gavage 19-22dpi does not alter locomotor recovery.”
Quote in the paperSubstantial claim - Interpretationreasoning
The contradiction is likely attributed to differences in the timing of dosing.
“These results contradict other CNS trauma studies that show tamoxifen improves anatomical and motor recovery in female and male SCI rodents [39–41, 55], but this is likely attributed to differences in the timing of dosing.”
Quote in the paperSubstantial claim - Interpretationown data
Axon myelination is not changed when tamoxifen is given short-term at the onset of endogenous remyelination.
“Collectively, these data show that axon myelination is not changed when tamoxifen is given short-term at the onset of endogenous remyelination.”
- Also stated in: § Discussion · plain
“However, our findings show that delayed tamoxifen did not impact myelination as the total number of oligodendrocytes, demyelinated axons, and remyelinated axons were not significantly different between groups.”
Quote in the paperSubstantial claim - Also stated in: § Discussion · plain
- Interpretationown data
Behavioral and histological changes observed following tamoxifen induced Cre-mediated recombination, at least in the fashion in which we gave it, are not due to tamoxifen treatment.
“These data are applicable to Cre mouse models and suggest that behavioral and histological changes observed following tamoxifen induced Cre-mediated recombination, at least in the fashion in which we gave it, are not due to tamoxifen treatment.”
Quote in the paperSubstantial claim - Premisecitation
White matter sparing directly correlates with hindlimb motor recovery.
“White matter sparing directly correlates with hindlimb motor recovery [71]; therefore, since locomotion was not changed by tamoxifen, it is not surprising that total spared white matter was also unaffected by tamoxifen.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [71] DM Basso, 1996, Graded Histological and Locomotor Outcomes after Spinal Cord Contusion Using the NYU Weight-Drop Device versus Transection, Exp Neurol source
- Interpretationreasoning
As expected, tamoxifen did not significantly alter the injury environment.
“Therefore, as expected, tamoxifen did not significantly alter the injury environment.”
Quote in the paperSubstantial claim - Interpretationown data
Tamoxifen does not have a lasting effect on cell proliferation.
“This argues that tamoxifen does not have a lasting effect on cell proliferation.”
Quote in the paperSubstantial claim - Interpretationcitation
It is not surprising that our data reveal ~25% of the NG2+ cells and CD68+ cells are EdU+ at 42pi.
“This significant increase in macrophage/microglia and NG2 cell proliferation is maintained for months post-injury [2, 44]; therefore, it is not surprising that our data reveal ~25% of the NG2+ cells and CD68+ cells are EdU+ at 42pi.”
Quote in the paperNot a substantial claim - Interpretationreasoning
The higher BMS subscore at 14dpi is likely because males achieved consistent plantar stepping on the BMS scale, which occurs when mice miss 5 or fewer steps during the 4-minute test.
“The higher subscore at 14dpi is likely because males achieved consistent plantar stepping on the BMS scale, which occurs when mice miss 5 or fewer steps during the 4-minute test.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Tamoxifen did not cause lasting sex-specific effects.
“Thus, tamoxifen did not cause lasting sex-specific effects.”
Quote in the paperSubstantial claim - Interpretationown data
Male mice gained fine motor control faster than females.
“This suggests that male mice gained fine motor control faster than females.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Giving tamoxifen to induce Cre-mediated recombination chronically after SCI should not interfere with experimental outcome measures.
“Therefore, giving tamoxifen to induce Cre-mediated recombination chronically after SCI should not interfere with experimental outcome measures.”
Quote in the paperSubstantial claim - Interpretationown data
The faster recovery was not due to a less severe injury.
“therefore, faster recovery was not due to a less severe injury.”
Quote in the paperSubstantial claim
- Classified as probably not a substantial claim. 30
- May combine two claims. 42
- The quote only partly states this claim. 1
Classified as probably not a substantial claim.
PremisecitationTamoxifen is a known repressor of astrocyte reactivity acutely after SCI.
“Tamoxifen is a known repressor of astrocyte reactivity acutely after SCI [42, 43, 55].”
Quote in the paperSubstantial claim2 of 3 sources checked- cites [42] JM Colón, 2018, Continuous tamoxifen delivery improves locomotor recovery 6 h after spinal cord injury by neuronal and glial mechanisms in male rats, Exp Neurol source
The Results section reports that tamoxifen enhanced GFAP expression, a marker of astrocyte reactivity, at 2 days after spinal cord injury compared with placebo. GFAP returned to placebo levels at 7 days and was significantly reduced only at 28 days. The paper therefore reports increased, not repressed, astrocytic reactivity at the acute time point. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites [43] J Guptarak, 2014, The cancer drug tamoxifen: A potential therapeutic treatment for spinal cord injury, J Neurotrauma source
- cites [55] JM Colón, 2016, Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats, J Neurotrauma source
The Results section reports that tamoxifen given immediately or 24 hours after SCI reduced GFAP-mediated reactive gliosis in female rats. However, GFAP was assessed 35 days after injury, so the paper does not establish that astrocyte reactivity was suppressed acutely. (LLM, conf=0.86)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationPrevious studies began tamoxifen treatment within 24 hours of injury, then gave low doses of tamoxifen chronically via intraperitoneal injection or intrathecal infusion.
“Previous studies began tamoxifen treatment within 24 hours of injury, then gave low doses of tamoxifen chronically via intraperitoneal injection [39, 41] or intrathecal infusion [40, 55].”
Quote in the paperSubstantial claim3 of 4 sources checked- cites [39] B de la Torre Valdovinos, 2016, Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats, J Vet Med source
Methods §2.2 reports tamoxifen at 1 mg/kg by intraperitoneal injection on days 0, 1, and 2 after injury, supporting early treatment and the route attributed to this source. It describes only a three-day course, not chronic treatment. The sentence assigns intrathecal infusion to other citations. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [41] DS Tian, 2009, Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats, J Neurochem source
- cites [40] L Mosquera, 2014, Tamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: Their antioxidant effect and role of estrogen receptor alpha, Brain Res source
Experimental Procedures §§4.2–4.3 report that this study began tamoxifen treatment seven days before spinal cord injury, using subcutaneous pellets that released the drug for 30 days—not treatment begun within 24 hours after injury by intraperitoneal injection or intrathecal infusion. The Discussion (§3.3) does mention other groups starting treatment 30 minutes or two hours after injury, but does not establish the claimed administration routes for this study. Page numbers are unavailable in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites [55] JM Colón, 2016, Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats, J Neurotrauma source
The 'Laminectomy, SCI, and drug administration' section reports treatment immediately or 24 hours after injury, with continuous release of 0.71 mg/day for 21 days. But it says the tamoxifen was delivered by subcutaneous pellets, not intraperitoneal injection or intrathecal infusion. No page number is available in our copy. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim. May combine two claims.
Premisecitation21 days of tamoxifen treatment beginning immediately after SCI reduced inflammation, decreased glial reactivity, promoted cell survival, increased white matter sparing, and enhanced functional recovery in rats and cats.
“21 days of tamoxifen treatment beginning immediately after SCI reduced inflammation, decreased glial reactivity, promoted cell survival, increased white matter sparing, and enhanced functional recovery in rats and cats [38–43].”
Quote in the paperSubstantial claim4 of 6 sources checked- cites [38] JM Colón, 2016, Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery, Neural Regen Res source
The “Physiological Effects of Chronic Spinal Cord Injury and Therapy Intervention” section reports immediate tamoxifen treatment delivered for 21 days and improved locomotion. “Tamoxifen, a Multi-active Drug to Target Spinal Cord Injury” reports anti-inflammatory and anti-gliotic effects, neuronal survival, white-matter sparing, and recovery across SCI studies. The copy does not establish that the 21-day regimen produced all those effects in both rats and cats; its cited cat study is identified for axonal preservation and gait recovery. Page numbers are unavailable in our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [39] B de la Torre Valdovinos, 2016, Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats, J Vet Med source
Methods (§2.2) says the cats received tamoxifen on days 0, 1, and 2 after injury, not for 21 days. Results (§§3.3–3.5) support neuronal and myelin preservation and improved gait in cats; the Discussion (§4) reports anti-inflammatory effects in rats from earlier work. This paper does not establish reduced glial reactivity or increased white matter sparing after the stated 21-day regimen in rats and cats. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [40] L Mosquera, 2014, Tamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: Their antioxidant effect and role of estrogen receptor alpha, Brain Res source
Results §2.6 and Discussion §3.3 report improved locomotor recovery and white-matter sparing in rats after SCI. But Experimental Procedures §§4.2–4.3 describe tamoxifen pellets implanted seven days before SCI and designed to release the drug for 30 days, not 21 days of treatment beginning immediately afterward. Discussion §3.3 discusses reduced inflammatory markers after SCI in other rat studies, while reduced gliosis and increased viable cells concern other brain-injury models; this paper provides no evidence for cats. (LLM, conf=0.91)
Experimental — accuracy not yet measured - cites [41] DS Tian, 2009, Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats, J Neurochem source
- cites [42] JM Colón, 2018, Continuous tamoxifen delivery improves locomotor recovery 6 h after spinal cord injury by neuronal and glial mechanisms in male rats, Exp Neurol source
The Methods and Results (page unavailable) support 21-day tamoxifen delivery beginning immediately after SCI in rats, with improved locomotion, neuronal survival, white-matter sparing, and reduced chronic gliosis. The Discussion describes anti-inflammatory effects as a possible mechanism, not a measured reduction in inflammation. It also reports improved gait in cats given three injections over 48 hours, not 21 days of treatment. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [43] J Guptarak, 2014, The cancer drug tamoxifen: A potential therapeutic treatment for spinal cord injury, J Neurotrauma source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationEdU at the dose used (0.2 mg/ml in drinking water) is nontoxic.
“EdU at this dose is nontoxic [45].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [45] KM Young, 2013, Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling, Neuron source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationTamoxifen injected intraperitoneally in adult female rats acutely after toxin-induced demyelination in the brain stimulated NG2+ oligodendrocyte progenitor cell differentiation into oligodendrocytes and accelerated the rate of remyelination.
“tamoxifen injected intraperitoneally in adult female rats acutely after toxin-induced demyelination in the brain stimulated NG2+ oligodendrocyte progenitor cell differentiation into oligodendrocytes [OLs] and accelerated the rate of remyelination [35].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [35] GA Gonzalez, 2016, Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system, Sci Rep source
Classified as probably not a substantial claim.
PremisecitationAs a consequence of primary and secondary injuries, myelin, neuron, and axon loss spreads rostral and caudal from the lesion epicenter and contributes to functional deficits.
“As a consequence of primary and secondary injuries, myelin, neuron, and axon loss spreads rostral and caudal from the lesion epicenter and contributes to functional deficits [52–54].”
Quote in the paperSubstantial claim1 of 3 sources checked- cites [52] CH Tator, 1995, Update on the Pathophysiology and Pathology of Acute Spinal Cord Injury, Brain Pathol source
- cites [53] CH Tator, 1991, Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms, Neurosurgery source
- cites [54] MC Wallace, 1987, Chronic regenerative changes in the spinal cord after cord compression injury in rats, Surg Neurol source
Classified as probably not a substantial claim.
PremisecitationTamoxifen administration immediately after SCI reduces this response in part by promoting cell survival.
“Studies have shown that tamoxifen administration immediately after SCI reduces this response in part by promoting cell survival [39, 41, 55].”
Quote in the paperSubstantial claim2 of 3 sources checked- cites [39] B de la Torre Valdovinos, 2016, Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats, J Vet Med source
The Methods (§2.2; page unavailable) report tamoxifen treatment beginning on the day of injury, and the Results (§3.4; page unavailable) report increased neuronal survival in treated cats. The Introduction describes tamoxifen as a proposed inflammatory-response modulator, but this study does not show that promoting cell survival is how it reduces that response. (LLM, conf=0.84)
Experimental — accuracy not yet measured - cites [41] DS Tian, 2009, Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats, J Neurochem source
- cites [55] JM Colón, 2016, Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats, J Neurotrauma source
The Abstract (page unavailable) reports that tamoxifen given immediately after SCI reduced secondary damage, including astrogliosis and cell death, in female rats. The Discussion (page unavailable) also reports reduced GFAP levels and cites evidence that tamoxifen attenuates neuronal apoptosis. It does not establish that promoting cell survival is the mechanism by which tamoxifen reduces the response. (LLM, conf=0.83)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationAfter SCI, axons become demyelinated and lose structured nodal domains as Caspr and Kv1.2 spread along the axon.
“After SCI, axons become demyelinated and lose these structured nodal domains as Caspr and Kv1.2 spread along the axon [61, 63].”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [61] S Karimi-Abdolrezaee, 2004, Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma, Eur J Neurosci source
- cites [63] IL Arancibia-Carcamo, 2014, The node of Ranvier in CNS pathology, Acta Neuropathol source
In “Pathologies of the paranode” (page unavailable), the paper says spinal cord injury can disrupt paranodes and retract myelin, moving Kv1 channels closer to elongated nodes. It does not say that Caspr and Kv1.2 both spread along axons after spinal cord injury; its report of decreased Caspr expression concerns multiple sclerosis. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim. May combine two claims.
PremisecitationTamoxifen exerts estrogen-agonistic effects on NG2 cells and estrogen-antagonist effects on monocytes, stimulating and repressing proliferation, respectively.
“Tamoxifen exerts estrogen-agonistic effects on NG2 cells and estrogen-antagonist effects on monocytes, stimulating and repressing proliferation, respectively [56–58].”
Quote in the paperSubstantial claim2 of 3 sources checked- cites [56] S Behjati, 2009, The effects of tamoxifen on immunity, Curr Med Chem source
The Pharmacology of Tamoxifen section says tamoxifen can act as an estrogen agonist in some tissues and an antagonist in others. But the Immune Modulator section does not discuss NG2 cells or repression of monocyte proliferation: it reports reduced T-cell proliferation induced by tamoxifen-treated monocyte-derived dendritic cells and suggests that effect is estrogen-independent. Page numbers were not available in our copy. (LLM, conf=0.82)
Experimental — accuracy not yet measured - cites [57] JY Lee, 2012, 17β-Estradiol Inhibits Apoptotic Cell Death of Oligodendrocytes by Inhibiting RhoA-JNK3 Activation after Spinal Cord Injury, Endocrinology source
The section on estrogen-receptor signaling describes 17β-estradiol and the antagonist ICI182780 after spinal cord injury, not tamoxifen. Searches for tamoxifen, NG2 cells, monocytes, and their proliferation found no passage addressing the claimed cell-specific effects in our copy (page unavailable). (LLM, conf=0.75)
Experimental — accuracy not yet measured - cites [58] M Marin-Husstege, 2004, Oligodendrocyte progenitor proliferation and maturation is differentially regulated by male and female sex steroid hormones, Dev Neurosci source
Classified as probably not a substantial claim.
PremisecitationMyelinated and demyelinated axons are often quantified via node of Ranvier labeling because myelin labels poorly with histology.
“Since myelin labels poorly with histology, myelinated and demyelinated axons are often quantified via node of Ranvier labeling [59].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [59] MA Marin, 2017, Reassembly of the axon initial segment and nodes of Ranvier regenerated axons of the central nervous system, Neural Regen Res source
The main text says the authors used caspr immunostaining of paranodal junctions as a surrogate for myelination in regenerated CNS axons; Figure 2 likewise calls paranodes a surrogate marker for remyelination. It does not say myelin labels poorly with histology or that node labeling is often used to quantify myelinated and demyelinated axons. The difficulty it identifies is distinguishing remyelination by electron microscopy when myelin debris remains after CNS injury. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim. May combine two claims.
PremisecitationIn the ethidium bromide model of demyelination, tamoxifen stimulates OL differentiation and increases the number of remyelinated axons in rats.
“In the ethidium bromide model of demyelination, tamoxifen stimulates OL differentiation and increases the number of remyelinated axons in rats [35].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [35] GA Gonzalez, 2016, Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system, Sci Rep source
May combine two claims.
PremisecitationImmediately after injury the spinal cord undergoes massive cellular and molecular changes, including increased cell death, infiltration of inflammation cells, axon degeneration, and OL and myelin loss.
“Immediately after injury the spinal cord undergoes massive cellular and molecular changes, including increased cell death [64, 65], infiltration of inflammation cells in the lesion [2–6], axon degeneration [7–10], and OL and myelin loss [13–16, 66, 67].”
Quote in the paperSubstantial claim3 of 10 sources checked- cites [64] MJ Crowe, 1997, Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys, Nat Med source
- cites [65] MS Beattie, 2002, Cell death in models of spinal cord injury, Prog Brain Res source
- cites [2] JC Fleming, 2006, The cellular inflammatory response in human spinal cords after injury, Brain source
- cites [3] DJ Donnelly, 2008, Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury, Exp Neurol source
- cites [4] PG Popovich, 1997, Cellular inflammatory response after spinal cord injury in Sprague- Dawley and Lewis rats, J Comp Neurol source
- cites [5] JM Schwab, 2014, The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury, Exp Neurol source
- cites [6] PG Popovich, 1993, Differential Expression of MHC Class II Antigen in the Contused Rat Spinal Cord, J Neurotrauma source
- cites [7] A Buss, 2004, Sequential loss of myelin proteins during Wallerian degeneration in the human spinal cord, Brain source
- cites [8] A Buss, 2003, Sequential loss of myelin proteins during Wallerian degeneration in the rat spinal cord, Glia source
- cites [9] F Sun, 2010, Effects of axon degeneration on oligodendrocyte lineage cells: Dorsal rhizotomy evokes a repair response while axon degeneration rostral to spinal contusion induces both repair and apoptosis, Glia source
May combine two claims.
PremisecitationTamoxifen was given 19-22dpi, which is after the glial scar has formed and most white matter, glial, and neuron loss has stabilized.
“Here, we gave tamoxifen 19-22dpi, which is after the glial scar has formed and most white matter, glial, and neuron loss has stabilized [66–70].”
Quote in the paperSubstantial claim2 of 5 sources checked- cites [66] DM McTigue, 2001, Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord, J Neurosci source
In “Oligodendrocytes are lost early after SCI at the epicenter” (page unavailable), the paper reports that 93% of epicenter oligodendrocytes were lost by day 7, supporting the claim that much glial loss occurred before days 19–22. It also reports a further reduction in oligodendrocyte numbers between days 14 and 28 and ongoing tissue cavitation. Our copy does not establish that a glial scar had formed or that white-matter and neuron loss had stabilized by days 19–22; the tamoxifen timing is the citing authors’ own procedure. (LLM, conf=0.79)
Experimental — accuracy not yet measured - cites [67] AG Rabchevsky, 2007, Temporal-spatial dynamics in oligodendrocyte and glial progenitor cell numbers throughout ventrolateral white matter following contusion spinal cord injury, Glia source
- cites [68] IB Wanner, 2013, Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury, J Neurosci source
The Results (page unavailable) say astroglial scar formation was essentially complete by 14 days after crush spinal cord injury, supporting the scar-timing part of the claim. The passages do not establish that white-matter, glial, and neuronal loss had mostly stabilized by 19–22 days. The citing authors’ tamoxifen schedule is their own procedure, not a finding attributed to this source. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [69] MT Fitch, 2008, CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure, Exp Neurol source
- cites [70] SD Grossman, 2001, Temporal-spatial pattern of acute neuronal and glial loss after spinal cord contusion, Exp Neurol source
Classified as probably not a substantial claim. May combine two claims.
InterpretationcitationSince tamoxifen promotes OL differentiation and remyelination, it is possible that inducing Cre-recombination with tamoxifen artificially inflates the extent of remyelination.
“Since tamoxifen promotes OL differentiation and remyelination [35], it is possible that inducing Cre-recombination with tamoxifen artificially inflates the extent of remyelination.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [35] GA Gonzalez, 2016, Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system, Sci Rep source
May combine two claims.
InterpretationcitationIt is possible that giving tamoxifen at 300 mg/kg, compared to 1 mg/kg, was toxic and induced neuronal cell death.
“Tamoxifen is known to be toxic to humans and rodents at high doses [72–74]; therefore, it is possible that giving tamoxifen at 300 mg/kg, compared to 1 mg/kg [39, 55], was toxic and induced neuronal cell death.”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites [39] B de la Torre Valdovinos, 2016, Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats, J Vet Med source
- cites [55] JM Colón, 2016, Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats, J Neurotrauma source
The Conclusions (page unavailable) report neuroprotective effects at 0.71 mg/day and refer to other studies using 1 mg/day, not 1 mg/kg. The neuronal-survival figure reports more surviving neurons after tamoxifen treatment, but the paper does not test 300 mg/kg or suggest that this dose induced neuronal cell death. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThis is opposite of previous reports that suggest tamoxifen is neuroprotective and increases neuron survival.
“This is opposite of previous reports that suggest tamoxifen is neuroprotective and increases neuron survival [39, 41, 42, 55].”
Quote in the paperNot a substantial claim3 of 4 sources checked- cites [39] B de la Torre Valdovinos, 2016, Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats, J Vet Med source
- cites [41] DS Tian, 2009, Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats, J Neurochem source
- cites [42] JM Colón, 2018, Continuous tamoxifen delivery improves locomotor recovery 6 h after spinal cord injury by neuronal and glial mechanisms in male rats, Exp Neurol source
- cites [55] JM Colón, 2016, Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats, J Neurotrauma source
Classified as probably not a substantial claim. May combine two claims.
PremisecitationEndogenous NG2 cells then proliferate and differentiate to replace lost OLs and remyelinate spared axons.
“Endogenous NG2 cells then proliferate and differentiate to replace lost OLs and remyelinate spared axons [13, 47, 66, 79, 80].”
Quote in the paperSubstantial claim1 of 5 sources checked- cites [13] RF Gledhill, 1973, W.I. M. Demyelination and Remyelination after Acute Spinal Cord Compression, Exp Neurol source
- cites [47] R Tripathi, 2007, Prominent oligodendrocyte genesis along the border of spinal contusion lesions, Glia source
- cites [66] DM McTigue, 2001, Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord, J Neurosci source
In “Possible roles for proliferating NG2+ progenitors after SCI,” the authors report increased NG2+ cell proliferation after injury. They explicitly say they did not determine whether those cells differentiated into mature oligodendrocytes and describe their role in replacement and remyelination as possible, not established. Page numbers are not provided in the supplied passages. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [79] LJ Zai, 2005, Cell proliferation and replacement following contusive spinal cord injury, Glia source
- cites [80] LL Horky, 2006, Fate of endogenous stem/progenitor cells following spinal cord injury, J Comp Neurol source
Classified as probably not a substantial claim.
PremisecitationTamoxifen is known to be toxic to humans and rodents at high doses.
“Tamoxifen is known to be toxic to humans and rodents at high doses [72–74]; therefore, it is possible that giving tamoxifen at 300 mg/kg, compared to 1 mg/kg [39, 55], was toxic and induced neuronal cell death.”
Quote in the paperSubstantial claim1 of 3 sources checked- cites [72] F Denk, 2015, Tamoxifen induces cellular stress in the nervous system by inhibiting cholesterol synthesis, Acta Neuropathol Commun source
The Results report that 75 mg/kg tamoxifen repeatedly stressed otherwise healthy mouse neurons, and the Introduction reports cognitive disturbances in some treated patients. But the paper does not establish toxicity in humans specifically at high doses; its Discussion says the consequences of a very-high-dose mouse regimen remain unknown. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [73] LA Kim, 2014, Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms, Investig Ophthalmol Vis Sci source
- cites [74] IY Kim, 1996, Loss Type Prostate of Expression II Receptors Cancer of Transforming Correlates Growth Tumor Factor Grade 3 Type in Human I and with TBR-I a, Clin Cancer Res
Classified as probably not a substantial claim.
PremisecitationThe Cre/lox system has been used in reporter mice to track oligodendrogenesis and myelin synthesis during development, after CNS demyelination, and after SCI.
“The Cre/lox system been used in reporter mice to track oligodendrogenesis and myelin synthesis during development [45, 81], after CNS demyelination [82, 83], and after SCI [44, 84, 85].”
Quote in the paperSubstantial claim6 of 7 sources checked- cites [45] KM Young, 2013, Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling, Neuron source
The Experimental Procedures ('Transgenic Mice and Cre Recombination'; page unavailable) describe crossing Pdgfra-CreERT2 mice with Cre-sensitive reporters. The Results ('Late-Born OLs Generate Many More, Shorter Internodes Than Early-Born OLs'; page unavailable) use those mice to track oligodendrocytes and myelin internodes from P30 onward. This supports the reporter-mouse method, but the paper chiefly studies postnatal and adult myelination rather than establishing its use during early development—the portion of the sentence to which this source appears attached. (LLM, conf=0.83)
Experimental — accuracy not yet measured - cites [81] LE Clarke, 2012, Properties and fate of oligodendrocyte progenitor cells in the corpus callosum, motor cortex, and piriform cortex of the mouse, J Neurosci source
The Methods (Transgenic mice) and Results (OPCs generate exclusively OLs in the postnatal mouse brain; page unavailable) show that the study used Cre-lox reporter mice to trace OPCs into oligodendrocytes in the postnatal brain. This supports the citation’s developmental oligodendrogenesis point, but the cited passages do not show that the reporters tracked myelin synthesis. The demyelination and SCI parts of the sentence have separate citations and are not attributed to this paper. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [82] M Zawadzka, 2010, CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination, Cell Stem Cell source
- cites [83] RB Tripathi, 2010, NG2 glia generate new oligodendrocytes but few astrocytes in a murine experimental autoimmune encephalomyelitis model of demyelinating disease, J Neurosci source
The Discussion reports using Cre-lox reporter mice to track new oligodendrocytes in an EAE demyelination model. But the Results state that the reporter did not label myelin sheaths and the authors could not determine whether the new oligodendrocytes formed myelin. The development and SCI portions of the sentence are attached to other citations. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [44] ZC Hesp, 2015, Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats, J Neurosci source
- cites [84] GJ Duncan, 2018, Locomotor recovery following contusive spinal cord injury does not require oligodendrocyte remyelination, Nat Commun source
- cites [85] P Assinck, 2017, Myelinogenic plasticity of oligodendrocyte precursor cells following spinal cord contusion injury, J Neurosci source
Classified as probably not a substantial claim. May combine two claims.
PremisecitationInjury to the spinal cord results in OL death and demyelination, which impairs neuronal signaling and limits functional recovery.
“Injury to the spinal cord results in OL death and demyelination, which impairs neuronal signaling and limits functional recovery [13, 61, 77, 78].”
Quote in the paperSubstantial claim1 of 4 sources checked- cites [13] RF Gledhill, 1973, W.I. M. Demyelination and Remyelination after Acute Spinal Cord Compression, Exp Neurol source
- cites [61] S Karimi-Abdolrezaee, 2004, Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma, Eur J Neurosci source
- cites [77] MO Totoiu, 2005, Spinal cord injury is accompanied by chronic progressive demyelination, J Comp Neurol source
- cites [78] R Nashmi, 2000, Abnormal axonal physiology is associated with altered expression and distribution of Kv1.1 and Kv1.2 K+ channels after chronic spinal cord injury, Eur J Neurosci source
The Introduction describes dysmyelinated axons after spinal cord injury with abnormal conduction, and the Proposed mechanism of axonal dysfunction links demyelination to possible conduction block. Our copy does not state that oligodendrocytes (OLs) die or establish that demyelination limits functional recovery. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationPhagocytic microglia and infiltrating macrophage proliferation increases 6-fold within the first week of injury compared to uninjured controls.
“Similarly, phagocytic microglia and infiltrating macrophage proliferation increases 6-fold within the first week of injury compared to uninjured controls [2, 4, 76].”
Quote in the paperNot a substantial claim2 of 3 sources checked- cites [2] JC Fleming, 2006, The cellular inflammatory response in human spinal cords after injury, Brain source
The quantitative-analysis section reports an almost sixfold increase at 1–3 days after injury compared with uninjured controls, but the measure was the area of CD68 immunoreactivity, not cell proliferation. The activation-and-infiltration section reports increased activated microglia at that time and only small numbers of infiltrating monocytes; it does not establish a sixfold increase in both cell populations. Page numbers are not provided in our copy. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [4] PG Popovich, 1997, Cellular inflammatory response after spinal cord injury in Sprague- Dawley and Lewis rats, J Comp Neurol source
- cites [76] AD Greenhalgh, 2014, Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord Injury and its effects on cell death, J Neurosci source
The section on microglial proliferation reports Ki67-positive cells at days 3, 5, and 7 after injury, supporting proliferation within the first week. Its approximately sevenfold figure compares microglial proliferation with infiltrating macrophage proliferation—not either cell type with uninjured controls. The claimed sixfold increase over controls is not supported. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S1 (asserted), S3 (load-bearing). May combine two claims.
PremisecitationFemale SCI rats recover faster and to a higher level than male SCI rats.
“other studies show that female SCI rats recover faster and to a higher level than male SCI rats”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [86] JP Datto, 2015, Female Rats Demonstrate Improved Locomotor Recovery and Greater Preservation of White and Gray Matter after Traumatic Spinal Cord Injury Compared to Males, J Neurotrauma source
- cites [87] M Farooque, 2006, Gender-related differences in recovery of locomotor function after spinal cord injury in mice, Spinal Cord source
May combine two claims.
PremisecitationStudies that report a neuroprotective effect of tamoxifen have given it during the acute phase, capitalizing on tamoxifen's ability to reduce inflammation, decrease glial reactivity, and promote cell survival.
“Studies that report a neuroprotective effect of tamoxifen have given it during this acute phase, capitalizing on tamoxifen’s ability to reduce inflammation, decrease glial reactivity, and promote cell survival [39–42, 55].”
Quote in the paperSubstantial claim4 of 5 sources checked- cites [39] B de la Torre Valdovinos, 2016, Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats, J Vet Med source
- cites [40] L Mosquera, 2014, Tamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: Their antioxidant effect and role of estrogen receptor alpha, Brain Res source
- cites [41] DS Tian, 2009, Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats, J Neurochem source
- cites [42] JM Colón, 2018, Continuous tamoxifen delivery improves locomotor recovery 6 h after spinal cord injury by neuronal and glial mechanisms in male rats, Exp Neurol source
The Introduction describes tamoxifen’s anti-inflammatory and neuroprotective effects, and the Discussion suggests that treatment during acute spinal cord injury may promote later neuronal survival. But the Results section, “Continuous TAM administration after SCI enhances gliosis in the acute stage,” reports increased GFAP expression at 2 days post-injury; reduced glial reactivity appeared in the chronic stage, not the acute stage. No page numbers are available in our copy. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [55] JM Colón, 2016, Tamoxifen Administration Immediately or 24 Hours after Spinal Cord Injury Improves Locomotor Recovery and Reduces Secondary Damage in Female Rats, J Neurotrauma source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationLess than 1% of glial cells divide in the uninjured rodent spinal cord.
“Less than 1% of glial cells divide in the uninjured rodent spinal cord [75]; however, after SCI, NG2 cell proliferation increases 50-fold as NG2 cells proliferate to replace NG2 cells and OLs lost from injury [44, 47].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [75] PJ Horner, 2000, Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord, J Neurosci source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationEstrogen stimulates cell proliferation and differentiation via the ERK pathway and the AKT/mTOR pathway.
“and stimulates cell proliferation and differentiation via the extracellular-signal-regulated kinase (ERK) pathway and the AKT/mammalian target of rapamycin (mTOR) pathway [90–93]”
Quote in the paperNot a substantial claim1 of 4 sources checked- cites [90] I Azcoitia, 2019, Molecular mechanisms and cellular events involved in the neuroprotective actions of estradiol. Analysis of sex differences, Front Neuroendocrinol source
- cites [91] YT Tsai, 2014, Extracellular signal-regulated kinase 1/2 is involved in a tamoxifen neuroprotective effect in a lateral fluid percussion injury rat model, J Surg Res source
- cites [92] L Yang, 2010, Extranuclear Estrogen Receptors Mediate the Neuroprotective Effects of Estrogen in the Rat Hippocampus. Bartolomucci A, editor, May 7 source
The Results section ('Inhibition of ERK and PI3K-Akt Signaling Abolishes EDC and E2-BSA Neuroprotection'; page unavailable) supports a role for ERK and Akt signaling in estrogen-receptor-mediated neuroprotection in rat hippocampal neurons. It does not establish that these pathways stimulate cell proliferation or differentiation, and the passages found do not identify an Akt/mTOR pathway. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [93] YJ Bao, 2011, 17Beta-estradiol differentially protects cortical pericontusional zone from programmed cell death after traumatic cerebral contusion at distinct stages via non-genomic and genomic pathways, Mol Cell Neurosci source
May combine two claims.
PremisecitationTamoxifen binds to the estrogen receptor and acts as an agonist in most CNS cells.
“Since tamoxifen binds to the estrogen receptor and acts as an agonist in most CNS cells [57, 58]”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [57] JY Lee, 2012, 17β-Estradiol Inhibits Apoptotic Cell Death of Oligodendrocytes by Inhibiting RhoA-JNK3 Activation after Spinal Cord Injury, Endocrinology source
The section ‘17β-Estradiol inhibits RhoA and JNK3 activation via ER’ discusses estradiol and the ER antagonist ICI182780, not tamoxifen. Searches for ‘tamoxifen’ and for agonist activity in CNS cells found no passage addressing whether tamoxifen binds ER or acts as an agonist in most CNS cells. Page numbers were not available in our copy. (LLM, conf=0.74)
Experimental — accuracy not yet measured - cites [58] M Marin-Husstege, 2004, Oligodendrocyte progenitor proliferation and maturation is differentially regulated by male and female sex steroid hormones, Dev Neurosci source
Classified as probably not a substantial claim.
PremisecitationEstrogen reduces cell death by reducing extracellular glutamate and reactive oxygen species.
“Estrogen reduces cell death by reducing extracellular glutamate and reactive oxygen species [88–90]”
Quote in the paperSubstantial claim2 of 3 sources checked- cites [88] P Karki, 2014, Astrocyte-derived growth factors and estrogen neuroprotection: Role of transforming growth factor-α in estrogen-induced upregulation of glutamate transporters in astrocytes, Mol Cell Endocrinol source
The Introduction and §5.1 (page unavailable) say estradiol enhances astrocytic glutamate transporters, which remove excess glutamate and help prevent excitotoxic neuronal death. Section 4.2 (page unavailable) also reports protection against oxidative stress-induced cell death, but does not say estrogen achieves that protection by reducing reactive oxygen species. The claimed ROS-reduction mechanism is therefore unsupported by our copy. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [89] K Strehlow, 2003, Modulation of antioxidant enzyme expression and function by estrogen, Circ Res source
The Abstract reports that 17β-estradiol reduced reactive oxygen species in vascular smooth muscle cells and describes how such species can contribute to apoptosis. It does not report reduced extracellular glutamate or demonstrate that estrogen reduced cell death; those parts of the claim are unsupported by this paper. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [90] I Azcoitia, 2019, Molecular mechanisms and cellular events involved in the neuroprotective actions of estradiol. Analysis of sex differences, Front Neuroendocrinol source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe faster recovery in female SCI rats may be due to higher levels of estrogen in females.
“which may be due to higher levels of estrogen in females [86, 87]”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [86] JP Datto, 2015, Female Rats Demonstrate Improved Locomotor Recovery and Greater Preservation of White and Gray Matter after Traumatic Spinal Cord Injury Compared to Males, J Neurotrauma source
The Discussion reports faster, more complete recovery in female rats and proposes that estrogen and/or progesterone may provide a neuroprotective advantage. It does not establish that the females had higher estrogen levels than the males, so the proposed hormonal explanation is supported but that specific comparison is not. (LLM, conf=0.83)
Experimental — accuracy not yet measured - cites [87] M Farooque, 2006, Gender-related differences in recovery of locomotor function after spinal cord injury in mice, Spinal Cord source
May combine two claims.
Findingown dataDelayed tamoxifen gavage from 19-22 dpi did not alter subsequent BMS scores, which were maintained at a 5.
“Corn oil or tamoxifen gavage from 19-22dpi did not alter subsequent BMS scores, which were maintained at a 5.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataTamoxifen treatment from 19-22 dpi did not change the lesion size or proportional area of GFAP+ cells surrounding the lesion in female or male mice.
“The data reveal that tamoxifen treatment from 19-22dpi did not change the lesion size (Fig 6A–6C) or proportional area (Fig 6A, 6B and 6D) of GFAP+ cells surrounding the lesion in female or male mice.”
- Also stated in: § Abstract · plain
“tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination”
Quote in the paperSubstantial claim- Also stated in: § Abstract · plain
The quote only partly states this claim.
Findingown dataThere were no significant differences in the spared white matter between any groups at 1 mm rostral to the epicenter, at the epicenter, or 1 mm caudal to the epicenter.
“There were no significant differences in the spared white matter between any groups (Fig 3B).”
- Also stated in: § Abstract · plain
“tamoxifen had no effect on white matter sparing”
Quote in the paperSubstantial claim- Also stated in: § Abstract · plain
May combine two claims.
Findingown dataBMS scores were not statistically different for drug administration or sex.
“BMS scores were not statistically different for drug administration or sex (Fig 2B).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataNeither analysis of intact nodes of Ranvier revealed significant differences between control and tamoxifen mice or between female and male mice.
“Neither analysis revealed significant differences between control and tamoxifen mice or between female and male mice.”
- Also stated in: § Delayed short-term tamoxifen gavage after SCI does not change total oligodendrocyte numbers, demyelination, or remyelination in the spared white matter · plain
“The data are not significantly different between groups at any distance from the lesion epicenter.”
Quote in the paperSubstantial claim- Also stated in: § Delayed short-term tamoxifen gavage after SCI does not change total oligodendrocyte numbers, demyelination, or remyelination in the spared white matter · plain
May combine two claims.
Findingown dataOf all EdU+ cells, ~21-26% were NG2+ and ~25% were CD68+ in control and tamoxifen female mice.
“Of all the EdU+ cells, ~21–26% were NG2+ and ~25% were CD68+ in control and tamoxifen female mice (Fig 7E and 7I).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataControl and tamoxifen mice scored similarly on the BMS scale and had a similar number of foot falls on the automated horizontal ladder.
“Although tamoxifen transiently increased lethargy, control and tamoxifen mice scored similarly on the BMS scale and had a similar number of foot falls on the automated horizontal ladder.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataA majority of axons were surrounded by thick myelin sheaths, and in smaller quantities, axons either had thin myelin sheaths, indicative of remyelination, or completely lacked myelin.
“A majority of axons were surrounded by thick myelin sheaths, and in smaller quantities, axons either had thin myelin sheaths, indicative of remyelination, or completely lacked myelin (Fig 9D–9F).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataSex had no effect on neuron number in the dorsal or ventral horn.
“Sex had no effect on neuron number in the dorsal or ventral horn (Fig 4C and 4D).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThe lesion epicenter had the least amount of EC staining with ~11% stained area, which increased 3-fold 1 mm rostral and caudal to the lesion.
“As expected, the lesion epicenter had the least amount of EC staining with ~11% stained area, which increased 3-fold 1 mm rostral and caudal to the lesion (Fig 3A and 3B).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataSimilarly, ~22-26% were NG2+ and ~20-25% were CD68+ in control and tamoxifen male mice.
“Similarly, ~22–26% were NG2+ and ~20–25% were CD68+ in control and tamoxifen male mice (Fig 7I).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataNeither sex nor tamoxifen administration lead to any significant differences in the number of OLs at the lesion border or in the distal white matter.
“In both groups, neither sex nor tamoxifen administration lead to any significant differences in the number of OLs at the lesion border or in the distal white matter (Fig 8A and 8B).”
- Also stated in: § Delayed short-term tamoxifen gavage after SCI does not change total oligodendrocyte numbers, demyelination, or remyelination in the spared white matter · plain
“Quantification of the total number of OLs 2 mm, 1mm, and 0.5 mm rostral and caudal to the lesion epicenter revealed no significant differences between groups.”
Quote in the paperSubstantial claim- Also stated in: § Delayed short-term tamoxifen gavage after SCI does not change total oligodendrocyte numbers, demyelination, or remyelination in the spared white matter · plain
May combine two claims.
Findingown dataThe number of vertical rears or speed of ambulation was not different between groups over time.
“The number of vertical rears or (G) speed of ambulation was not different between groups over time.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataTamoxifen transiently increased lethargy.
“Although tamoxifen transiently increased lethargy, control and tamoxifen mice scored similarly on the BMS scale and had a similar number of foot falls on the automated horizontal ladder.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataNeither tamoxifen nor sex had an effect on axonal sprouting.
“Neither tamoxifen nor sex had an effect on axonal sprouting.”
- Also stated in: § Abstract · plain
“tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination”
Quote in the paperSubstantial claim- Also stated in: § Abstract · plain
May combine two claims.
Findingown dataCorn oil- and tamoxifen-gavaged mice had comparable values for lesion size and astrocyte reactivity.
“Corn oil- and tamoxifen-gavaged mice had comparable values for lesion size and astrocyte reactivity.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataNeuronal cell counts were the only significant difference recorded in this study, with tamoxifen mice having fewer neurons overall in the dorsal and ventral horn compared to control mice.
“Neuronal cell counts were the only significant difference recorded in this study, with tamoxifen mice having fewer neurons overall in the dorsal and ventral horn compare to control mice.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataSex did not impact BMS scores, foot falls on the horizontal ladder, or activity.
“Similarly, sex did not impact BMS scores, foot falls on the horizontal ladder, or activity.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThere were no significant differences in contusion force, displacement, or area under curve.
“Contusion analyses from the Infinite Horizon device revealed no significant differences in force, displacement, or area under curve (data available in data repository)”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataDuring BMS testing, 5 of 19 female mice experienced 'butt down' spasms, whereas no male mice did.
“During BMS testing, 5 of 19 female mice experienced a common spasm known as “butt down” during which they lose weight support on their hindlimbs, resulting in missed steps that dropped their BMS subscore; no male mice experienced “butt down.””
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataDelayed 4-day tamoxifen gavage does not increase white matter sparing, neuron survival, axon sprouting, or axon number.
“Taken together, these data indicate that delayed 4-day tamoxifen gavage does not increase white matter sparing, neuron survival, axon sprouting, or axon number.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductown dataTwo raters blind to study groups scored locomotor performance.
“Two raters blind to study groups scored locomotor performance over 4 min considering ankle movement, weight support, plantar stepping, coordination, paw position, and trunk stability.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataDelayed short-term tamoxifen treatment is not neuroprotective and does not alter motor recovery in male or female mice after SCI.
“The data reveal that delayed short-term tamoxifen treatment is not neuroprotective and does not alter motor recovery in male or female mice after SCI.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenOne male mouse from each group died before sacrifice for unknown reasons.
“One male mouse from each group died before sacrifice for unknown reasons.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataThe peak displacement for one male mouse and one female mouse was greater than two standard deviations from the mean, so these mice were considered outliers and excluded from the study.
“The peak displacement for one male mouse and one female mouse was greater than two standard deviations from the mean, so these mice were considered outliers and excluded from the study.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductnone givenMice were randomly divided into tamoxifen or control groups.
“At 19 days post-injury, mice were randomly divided into tamoxifen or control groups.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataTamoxifen was given after spontaneous motor recovery ceased, which may explain a lack of effect of tamoxifen on locomotion.
“Thus, tamoxifen was given after spontaneous motor recovery ceased, which may explain a lack of effect of tamoxifen on locomotion.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataDelayed tamoxifen administration after SCI does not change functional recovery or improve tissue sparing in female or male mice.
“These data suggest that delayed tamoxifen administration after SCI does not change functional recovery or improve tissue sparing in female or male mice.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Study design and conductnone givenAll protocols have been verified with no-primary and no-secondary controls.
“All protocols have been verified with no-primary and no-secondary controls.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAll data were collected and analyzed in a blinded manner.
“All data were collected and analyzed in a blinded manner.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
InterpretationcitationIt is possible that the number of proliferating cells did not change due to offsetting agonist and antagonist effects of tamoxifen.
“Therefore, it is possible that the number of proliferating cells did not change due to offsetting agonist and antagonist effects.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningSince locomotion was not changed by tamoxifen, it is not surprising that total spared white matter was also unaffected by tamoxifen.
“White matter sparing directly correlates with hindlimb motor recovery [71]; therefore, since locomotion was not changed by tamoxifen, it is not surprising that total spared white matter was also unaffected by tamoxifen.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataThese data indicate that new myelin in reporter mice is formed from endogenous remyelination, and not induced by tamoxifen.
“These data indicate that new myelin in reporter mice is formed from endogenous remyelination, and not induced by tamoxifen.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataDelayed short-term tamoxifen gavage does not alter functional recovery, neuroprotection, or neurorestoration after SCI.
“Taken together, these data support our hypothesis that delayed short-term tamoxifen gavage does not alter functional recovery, neuroprotection, or neurorestoration after SCI.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe sex difference in BMS subscores cannot be attributed to tamoxifen because male BMS subscores were only higher at 14dpi, which was before drug treatment.
“Importantly, this difference cannot be attributed to tamoxifen since male BMS subscores were only higher 14dpi which was before drug treatment.”
Quote in the paperSubstantial claim
The paper relies on this without support.
Tamoxifen administration is necessary to gain temporal control of gene activation/deactivation in transgenic mouse models.
“Giving tamoxifen to transgenic mouse models is necessary to gain temporal control of activating and deactivating genes in specific cells.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
EdU administration overlapped tamoxifen treatment
MinorThe Results say EdU was given after tamoxifen treatment, but the stated schedules overlap on days 21 and 22 post-injury.
“In this study, EdU was given after tamoxifen treatment to evaluate potential tamoxifen effects on cell proliferation at varying distances from the lesion epicenter.”
“EdU was dissolved in the drinking water (0.2 mg/ml) and administered to mice from 21–42 days post-SCI via light-protected water bottles.”
Statistical methods conflict with the Figure 6 astrocyte analysis
MinorThe Methods specify a mixed-effect model with a Šídák post hoc test for astrocyte reactivity, while Figure 6 reports a one-way ANOVA with a Tukey post hoc test for GFAP reactivity and lesion area.
“Astrocyte reactivity, proliferating cell counts, OL counts, node of Ranvier counts, and axon myelination were analyzed by a mixed-effect model followed by the Šídák post hoc test because missing values that resulted from wrinkled or missing sections.”
“Quantification of (C) lesion area and (D) GFAP proportional area revealed no significant differences between groups. Data presented as mean + SEM. One-way ANOVA with Tukey post hoc test;”
Statistical methods conflict with the Figure 4 analysis
MinorThe Methods specify repeated-measures two-way ANOVA for neuron counts, whereas the Figure 4 caption identifies a mixed-effects analysis.
“Behavioral data, white matter sparing, axon counts, and neuron counts were analyzed by repeated measures two-way ANOVA followed by the Šídák post hoc test.”
“Mixed-effects analysis with Šídák post hoc test; corn oil female n = 6; tamoxifen female n = 7; corn oil male n = 5; tamoxifen male n = 6.”
Figure 4 says neuronal survival is unchanged despite significant neuron loss
MinorThe Figure 4 heading says neuronal survival does not change, but the same caption reports significantly fewer neurons in tamoxifen-treated mice in both the dorsal and ventral horn.
“Fig 4 Neuronal survival after SCI does not change with delayed tamoxifen treatment.”
“Tamoxifen mice had significantly fewer NeuN+ cells in the (C) dorsal horn (p = 0.0438) and the (D) ventral horn overall compared to control mice (p = 0.0431).”
Figure 9 cites the neuron figure for axon area
MinorFigure 9 says its node counts were normalized to percent axon area in Figure 4, but Figure 4 presents neuronal counts; percent axon area is presented in Figure 5.
“(C) Number of intact nodes of Ranvier normalized to percent axon area (Fig 4) in the lateral white matter at each sampled region.”
“Fig 5 Delayed tamoxifen treatment does not alter total axon area after SCI.”
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,478 · see citing works
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442 · see citing works
Regeneration beyond the glial scar
Silver, J., & Miller, J. H. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1326 · Cited by 3,090 · see citing works
Vogel, V. G. (2006) · JAMA · doi:10.1001/jama.295.23.joc60074 · Cited by 1,652 · see citing works
Basso, D., Fisher, L., Anderson, A., Jakeman, L., McTigue, D. M., & Popovich, P. (2006) · Journal of Neurotrauma · doi:10.1089/neu.2006.23.635 · Cited by 1,615 · see citing works
Self-citationReactive Astrocytes Protect Tissue and Preserve Function after Spinal Cord Injury
Faulkner, J., Herrmann, J., Woo, M. J., Tansey, K., Doan, N., & Sofroniew, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3547-03.2004 · Cited by 1,600 · see citing works
Tator, C. H., & Fehlings, M. G. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.75.1.0015 · Cited by 1,577 · see citing works
Basso, D. M., Beattie, M. S., & Bresnahan, J. C. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0098 · Cited by 1,470 · see citing works
Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms
Alizadeh, A., Dyck, S. M., & Karimi‐Abdolrezaee, S. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00282 · Cited by 1,447 · see citing works
Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys
Crowe, M. J., Bresnahan, J. C., Shuman, S. L., Masters, J. N., & Beattie, M. S. (1997) · Nature Medicine · doi:10.1038/nm0197-73 · Cited by 1,153 · see citing works
Estrogen and the Risk of Breast Cancer
Clemons, M., & Goss, P. E. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101253440407 · Cited by 1,100 · see citing works
Fitch, M. T., & Silver, J. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.014 · Cited by 1,007 · see citing works
Donnelly, D. J., & Popovich, P. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.009 · Cited by 995 · see citing works
Ligand-activated site-specific recombination in mice.
Feil, R., Brocard, J., Mascrez, B., LeMeur, M., Metzger, D., & Chambon, P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10887 · Cited by 907 · see citing works
Spinal Cord Injury Facts and Figures at a Glance
(2013) · Journal of Spinal Cord Medicine · doi:10.1179/1079026813z.000000000136 · Cited by 900 · see citing works
Oligodendrocyte Dynamics in the Healthy Adult CNS: Evidence for Myelin Remodeling
Young, K. M., Psachoulia, K., Tripathi, R. B., Dunn, S.-J., Cossell, L., Attwell, D., Tohyama, K., & Richardson, W. D. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.006 · Cited by 872 · see citing works
The cellular inflammatory response in human spinal cords after injury
Fleming, J. C., Norenberg, M. D., Ramsay, D. A., Dekaban, G. A., Marcillo, A. E., Saenz, A. D., Pasquale-Styles, M., Dietrich, W. D., & Weaver, L. C. (2006) · Brain · doi:10.1093/brain/awl296 · Cited by 847 · see citing works
Wanner, I. B., Anderson, M. A., Song, B., Levine, J., Fernandez, A., Gray-Thompson, Z., Ao, Y., & Sofroniew, M. V. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2121-13.2013 · Cited by 839 · see citing works
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 832 · see citing works
Proliferation and Differentiation of Progenitor Cells Throughout the Intact Adult Rat Spinal Cord
Horner, P. J., Power, A. E., Kempermann, G., Kuhn, H. G., Palmer, T. D., Winkler, J., Thal, L. J., & Gage, F. H. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-06-02218.2000 · Cited by 777 · see citing works
Indra, A. K., Warot, X. M., Brocard, J., Bornert, J., Xiao, J. H., Chambon, P., & METZGER, D. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.22.4324 · Cited by 758 · see citing works
Zawadzka, M., Rivers, L. E., Fancy, S. P. J., Zhao, C., Tripathi, R., Jamen, F., Young, K., Goncharevich, A., Pohl, H., Rizzi, M., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.04.002 · Cited by 650 · see citing works
In vivo imaging of axonal degeneration and regeneration in the injured spinal cord
Kerschensteiner, M., Schwab, M. E., Lichtman, J. W., & Misgeld, T. (2005) · Nature Medicine · doi:10.1038/nm1229 · Cited by 582 · see citing works
Metzger, D., Clifford, J., Chiba, H., & Chambon, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6991 · Cited by 570 · see citing works
Modulation of Antioxidant Enzyme Expression and Function by Estrogen
Strehlow, K., Rotter, S., Wassmann, S., Adam, O., Grohé, C., Laufs, K., Böhm, M., & Nickenig, G. (2003) · Circulation Research · doi:10.1161/01.res.0000082334.17947.11 · Cited by 483 · see citing works
Update on the Pathophysiology and Pathology of Acute Spinal Cord Injury
Tator, C. H. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00619.x · Cited by 478 · see citing works
Chapter 4 Cell death in models of spinal cord injury
Beattie, M. S., Hermann, G. E., Rogers, R. C., & Bresnahan, J. C. (2002) · Progress in Brain Research · doi:10.1016/s0079-6123(02)37006-7 · Cited by 453 · see citing works
McTigue, D. M., Wei, P., & Stokes, B. T. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-03392.2001 · Cited by 423 · see citing works
Self-citationSpinal cord injury is accompanied by chronic progressive demyelination
Totoiu, M. O., & Keirstead, H. S. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20517 · Cited by 372 · see citing works
Einheber, S., Zanazzi, G., Ching, W., Scherer, S., Milner, T. A., Peles, E., & Salzer, J. L. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.6.1495 · Cited by 369 · see citing works
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238648.23538.42 · Cited by 329 · see citing works
Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre, M., & Smith, C. L. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38923-2 · Cited by 320 · see citing works
Guest, J. D., Hiester, E. D., & Bunge, R. P. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.033 · Cited by 311 · see citing works
Temporal–Spatial Pattern of Acute Neuronal and Glial Loss after Spinal Cord Contusion
Grossman, S. D., Rosenberg, L. J., & Wrathall, J. R. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7628 · Cited by 310 · see citing works
Greenhalgh, A. D., & David, S. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4912-13.2014 · Cited by 296 · see citing works
Tripathi, R. B., Rivers, L. E., Young, K. M., Jamen, F., & Richardson, W. D. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3411-10.2010 · Cited by 277 · see citing works
Schwab, J. M., Zhang, Y., Kopp, M. A., Brommer, B., & Popovich, P. G. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.023 · Cited by 260 · see citing works
Fate of endogenous stem/progenitor cells following spinal cord injury
Horky, L. L., Galimi, F., Gage, F. H., & Horner, P. J. (2006) · Journal of Comparative Neurology · doi:10.1002/cne.21065 · Cited by 258 · see citing works
Cell proliferation and replacement following contusive spinal cord injury
Zai, L. J., & Wrathall, J. R. (2005) · Glia · doi:10.1002/glia.20176 · Cited by 240 · see citing works
Tee, M. K., Rogatsky, I., Tzagarakis-Foster, C., Čvoro, A., An, J., Christy, R. J., Yamamoto, K. R., & Leitman, D. C. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-06-0360 · Cited by 230 · see citing works
Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs
Yang, G., Nowsheen, S., Aziz, K., & Georgakilas, A. G. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.005 · Cited by 190 · see citing works
The Nodes of Ranvier: Molecular Assembly and Maintenance
Rasband, M. N., & Peles, E. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020495 · Cited by 190 · see citing works
Nashmi, R., & Fehlings, M. G. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00009-4 · Cited by 186 · see citing works
Clarke, L. E., Young, K. M., Hamilton, N. B., Li, H., Richardson, W. D., & Attwell, D. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0928-12.2012 · Cited by 182 · see citing works
Demyelination and remyelination after acute spinal cord compression
Gledhill, R. F., Harrison, B. M., & McDonald, W. I. (1973) · Experimental Neurology · doi:10.1016/0014-4886(73)90169-6 · Cited by 181 · see citing works
The node of Ranvier in CNS pathology
Arancibia-Carcamo, I. L., & Attwell, D. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1305-z · Cited by 177 · see citing works
(1996) · PubMed · Cited by 166 · see citing works
Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats
Hesp, Z. C., Goldstein, E. A., Miranda, C. J., Kaspar, B. K., & McTigue, D. M. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2568-14.2015 · Cited by 164 · see citing works
Self-citationYang, L.-C., Zhang, Q.-G., Zhou, C.-F., Yang, F., Zhang, Y.-D., Wang, R.-M., & Brann, D. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009851 · Cited by 163 · see citing works
Myelinogenic Plasticity of Oligodendrocyte Precursor Cells following Spinal Cord Contusion Injury
Assinck, P., Duncan, G. J., Plemel, J. R., Lee, M. J., Stratton, J. A., Manesh, S. B., Liu, J., Ramer, L. M., Kang, S. H., Bergles, D. E., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2409-16.2017 · Cited by 151 · see citing works
Pfaffl, M. W., Lange, I. G., Daxenberger, A., & MEYER, H. H. D. (2001) · Apmis · doi:10.1034/j.1600-0463.2001.090503.x · Cited by 149 · see citing works
Prominent oligodendrocyte genesis along the border of spinal contusion lesions
Tripathi, R., & McTigue, D. M. (2007) · Glia · doi:10.1002/glia.20491 · Cited by 131 · see citing works
Self-citationMarin-Husstege, M., Muggironi, M., Raban, D., Skoff, R. P., & Casaccia-Bonnefil, P. (2004) · Developmental Neuroscience · doi:10.1159/000082141 · Cited by 129 · see citing works
Azcoitia, I., Barreto, G. E., & Garcia-Segura, L. M. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100787 · Cited by 125 · see citing works
The Effects of Tamoxifen on Immunity
Behjati, S., & Frank, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803042 · Cited by 116 · see citing works
Cre recombinase-mediated site-specific recombinationbetween plant chromosomes.
Qin, M., Bayley, C., Stockton, T., & Ow, D. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1706 · Cited by 113 · see citing works
Duncan, G. J., Manesh, S. B., Hilton, B. J., Assinck, P., Liu, J., Moulson, A., Plemel, J. R., & Tetzlaff, W. (2018) · Nature Communications · doi:10.1038/s41467-018-05473-1 · Cited by 113 · see citing works
Gender-related differences in recovery of locomotor function after spinal cord injury in mice
Farooque, M., Suo, Z., Arnold, P. M., Wulser, M. J., Chou, C.-T., Vancura, R. W., Fowler, S., & Festoff, B. W. (2006) · Spinal Cord · doi:10.1038/sj.sc.3101816 · Cited by 112 · see citing works
Sequential loss of myelin proteins during Wallerian degeneration in the human spinal cord
Buss, A. (2004) · Brain · doi:10.1093/brain/awh355 · Cited by 111 · see citing works
Arvanian, V. L., Schnell, L., Lou, L., et al. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.01.004 · Cited by 109 · see citing works
Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion
Kimelberg, H. K., Feustel, P. J., Jin, Y., Paquette, J., Boulos, A., Keller, R. W., & Tranmer, B. I. (2000) · NeuroReport · doi:10.1097/00001756-200008210-00014 · Cited by 108 · see citing works
Tamoxifen mimics the effects of estradiol on food intake, body weight, and body composition in rats
Wade, G. N., & Heller, H. (1993) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1993.264.6.r1219 · Cited by 106 · see citing works
Tian, D., Liu, J., Xie, M., Zhan, Y., Qu, W., Yu, Z., Tang, Z., Pan, D., & Wang, W. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06077.x · Cited by 98 · see citing works
Schonberg, D. L., Popovich, P. G., & McTigue, D. M. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815c2530 · Cited by 97 · see citing works
Self-citationDatto, J. P., Bastidas, J. C., Miller, N. L., Shah, A. K., Arheart, K. L., Marcillo, A. E., Dietrich, W. D., & Pearse, D. D. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3702 · Cited by 96 · see citing works
Chronic regenerative changes in the spinal cord after cord compression injury in rats
Wallace, M. C., Tator, C. H., & Lewis, A. J. (1987) · Surgical Neurology · doi:10.1016/0090-3019(87)90031-0 · Cited by 95 · see citing works
Karimi‐Abdolrezaee, S., Eftekharpour, E., & Fehlings, M. G. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03164.x · Cited by 91 · see citing works
Antagonistic and agonistic effects of tamoxifen: significance in human cancer.
Gallo, M. A., & Kaufman, D. (1997) · PubMed · Cited by 87 · see citing works
Nashmi, R., Jones, O. T., & Fehlings, M. G. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00926.x · Cited by 85 · see citing works
Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system
Gonzalez, G. A., Hofer, M. P., Syed, Y. A., Amaral, A. I., Rundle, J., Rahman, S., Zhao, C., & Kotter, M. R. N. (2016) · Scientific Reports · doi:10.1038/srep31599 · Cited by 82 · see citing works
Sequential loss of myelin proteins during Wallerian degeneration in the rat spinal cord
Buss, A., & Schwab, M. E. (2003) · Glia · doi:10.1002/glia.10220 · Cited by 76 · see citing works
Mosquera, L., Colón, J. M., Santiago, J. M., Torrado, A. I., Meléndez, M., Segarra, A. C., Rodríguez-Orengo, J. F., & Miranda, J. D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.002 · Cited by 74 · see citing works
Karki, P., Smith, K., Johnson, J., & Lee, E. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.01.010 · Cited by 73 · see citing works
Church, J. S., Milich, L. M., Lerch, J. K., Popovich, P. G., & McTigue, D. M. (2017) · Glia · doi:10.1002/glia.23132 · Cited by 72 · see citing works
Self-citationRabchevsky, A. G., Sullivan, P. G., & Scheff, S. W. (2007) · Glia · doi:10.1002/glia.20508 · Cited by 59 · see citing works
Lee, J. Y., Choi, S. Y., Oh, T. H., & Yune, T. Y. (2012) · Endocrinology · doi:10.1210/en.2012-1068 · Cited by 57 · see citing works
Kim, L. A., Amarnani, D., Gnanaguru, G., Tseng, W. A., Vavvas, D. G., & D'Amore, P. A. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13662 · Cited by 47 · see citing works
Tamoxifen induces cellular stress in the nervous system by inhibiting cholesterol synthesis
Denk, F., Ramer, L. M., Erskine, E. L. K. S., Nassar, M. A., Bogdanov, Y., Signore, M., Wood, J. N., McMahon, S. B., & Ramer, M. S. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0255-6 · Cited by 44 · see citing works
Differential Expression of MHC Class II Antigen in the Contused Rat Spinal Cord
POPOVICH, P. G., STREIT, W. J., & STOKES, B. T. (1993) · Journal of Neurotrauma · doi:10.1089/neu.1993.10.37 · Cited by 42 · see citing works
Biegon, A. R., Brewster, M. E., Degani, H., Pop, E., Sömjen, D., & Kaye, A. M. (1996) · PubMed · Cited by 41 · see citing works
Long-term use of tamoxifen reduces the risk of dementia: A nationwide population-based cohort study
Sun, L.-M., Chen, H.-J., Liang, J.-A., & Kao, C.-H. (2016) · QJM · doi:10.1093/qjmed/hcv072 · Cited by 39 · see citing works
The cancer drug tamoxifen: A potential therapeutic treatment for spinal cord injury
Guptarak, J., Wiktorowicz, J. E., Sadygov, R. G., Zivadinovic, D., Paulucci-Holthauzen, A. A., Vergara, L., & Nesic, O. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3108 · Cited by 38 · see citing works
Sun, F., Lin, C. G., Mctigue, D., Shan, X., Tovar, C. A., Bresnahan, J. C., & Beattie, M. S. (2010) · Glia · doi:10.1002/glia.21009 · Cited by 38 · see citing works
Self-citationMickley, K. R., & Dluzen, D. E. (2004) · Neuroendocrinology · doi:10.1159/000079710 · Cited by 36 · see citing works
Colón, J. M., Torrado, A. I., Cajigas, Á., Santiago, J. M., Salgado, I. K., Arroyo, Y., & Miranda, J. D. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4111 · Cited by 35 · see citing works
Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery
Miranda, J., & Colón, J. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.189164 · Cited by 35 · see citing works
Risk of Parkinson's disease after tamoxifen treatment
Latourelle, J. C., Dybdahl, M., DeStefano, A. L., Myers, R. H., & Lash, T. L. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-23 · Cited by 31 · see citing works
Bao, Y.-J., Li, L.-Z., Li, X.-G., & Wang, Y.-J. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.07.004 · Cited by 30 · see citing works
Tsai, Y.-T., Wang, C.-C., Leung, P.-O., Lin, K.-C., Chio, C.-C., Hu, C.-Y., & Kuo, J.-R. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.02.009 · Cited by 25 · see citing works
Colón, J. M., González, P. A., Cajigas, Á., Maldonado, W. I., Torrado, A. I., Santiago, J. M., Salgado, I. K., & Miranda, J. D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.006 · Cited by 19 · see citing works
Tamoxifen Promotes Axonal Preservation and Gait Locomotion Recovery after Spinal Cord Injury in Cats
de la Torre Valdovinos, B., Duenas Jimenez, J. M., Estrada, I. J., Banuelos Pineda, J., Franco Rodriguez, N. E., Lopez Ruiz, J. R., Osuna Carrasco, L. P., Candanedo Arellano, A., & Duenas Jimenez, S. H. (2016) · Journal of Veterinary Medicine · doi:10.1155/2016/9561968 · Cited by 16 · see citing works
Lim, S.-W., Tt, E. N., Hu, C.-Y., Chio, C., Wang, C.-C., & Kuo, J.-R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.01.036 · Cited by 14 · see citing works
Marin, M., & Rasband, M. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.213543 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury
Shvetcov, A., Ruitenberg, M. J., Delerue, F., Gold, W. A., Brown, D. A., & Finney, C. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105074 · Cited by 52 · see citing works
Pukos, N., Marion, C. M., Arnold, W. D., Noble, B. T., Popovich, P. G., & McTigue, D. M. (2023) · Glia · doi:10.1002/glia.24382 · Cited by 30 · see citing works
Self-citationA review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study
Chen, M., Zhao, F.-L., Chu, W.-L., Bai, M., & Zhang, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115045 · Cited by 25 · see citing works
Otto, L., Russart, K. L. G., Kulkarni, P., McTigue, D. M., Ferris, C. F., & Pyter, L. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.798704 · Cited by 14 · see citing works
“org 5 immunolabeled for Iba1 or GFAP as previously described (Invitrogen) (57).”
MethodSelf-citationGoodus, M. T., Alfredo, A. N., Carson, K. E., Dey, P., Pukos, N., Schwab, J. M., Popovich, P. G., Gao, J., Mo, X. M., Bruno, R. S., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114847 · Cited by 12 · see citing works
“Oligodendrocytes were visualized with anti-GST π (Biorbyt, orb18037, 1:1000) as previously described (Pukos and McTigue, 2020).”
Self-citationSaldivia, N., Heller, G., Zelada, D., Whitehair, J., Venkat, N., Konjeti, A., Savitzky, R., Samano, S., Simchuk, D., van Breemen, R. B., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.035 · Cited by 6 · see citing works
Swarts, E. A., Munro, A. I., Bannerman, C. A., Zielonka, J. R., Tordoff, C. E., Ghasemlou, N., & Brennan, F. H. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115417 · Cited by 3 · see citing works
Ricardo, C. G., Ortega‐Camarillo, C., Contreras‐Ramos, A., Guadalupe, D. R., Alejandro, A. R., Pérez‐Rivero, J. J., & Vergara-Onofre, M. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138206 · Cited by 1 · see citing works
Vidaković, E., Bamberg, E., Zörner, B., Ostheim, K., Minder, B., Bertschy, S., Pannek, J., Stute, P., & Glisic, M. (2026) · Spinal Cord · doi:10.1038/s41393-026-01201-5
“More-over, the severity of mechanical allodynia positively correlated with gliosis, further supporting a protective role for estrogen in modulating glial responses to injury [59].”
- Authors
- Pukos, N., & McTigue, D. M.
- Affiliations
- The Ohio State University (US)
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- McTigue, Dana M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-07-31
- Volume
- 15
- Issue
- 7
- Pages
- e0235232
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7394399
- OpenAlex
- W3046572100
- Semantic Scholar
- 5a173ed8140186648d7eb6f5525cc0f238f8a6e1
- Cited by
- 9
- References
- 94
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Neurological Disorders and Stroke (NS100522, P30 NS104177)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Spinal Cord Injury Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Keywords
- tamoxifen, spinal cord injury, treatment delay, remyelination, neuroprotection, oligodendrocytes, white matter sparing, sex differences, Cre-loxP system, axonal sprouting
- MeSH terms
- Remyelination, Administration, Oral, Animals, Disease Models, Animal, Female, Hindlimb, Humans, Male, Motor Activity, Neurons, Oligodendroglia, Sex Factors, Spinal Cord Injuries, Tamoxifen, Recovery of Function, Cell Proliferation, Mice, Neurogenesis, Time-to-Treatment, Spinal Cord Dorsal Horn, Spinal Cord Ventral Horn
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-11.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-11.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
